Axiom will be closed on Wednesday August 30th due to Hurricane Idalia, we are praying that you, your family, and our beautiful Tampa are going to be safe and protected. We are planning on opening on Thursday August 31st.

Enrolling Studies
Axiom is currently enrolling patients in Multiple Sclerosis, Alzheimer’s Disease, Essential Tremor and Migraine studies.
If you or a loved one would be interested in participating in a study for any of the listed fields, or if you would like more information on our studies, please contact us at kristen.hibbett@axiomclinical.com or
813-353-9613.

CURRENTLY ENROLLING STUDIES
Alzheimer's Disease
1-A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.
ClinicalTrials.gov Identifier: NCT04592874
2- New IDEAS: Imaging Dementia—Evidence for Amyloid Scanning Study A Study to Improve Precision in Amyloid PET Coverage and Patient Care.
ClinicalTrials.gov Identifier: NCT04426539
3- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants with Mild Cognitive Impairment or Mild Dementia Due to Alzheimer’s Disease.
ClinicalTrials.gov Identifier: NCT05619692
https://alzheimerslightwavestudy.com/
Multiple Sclerosis
1- A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension.
ClinicalTrials.gov Identifier: NCT04926818
2- A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
ClinicalTrials.gov Identifier: NCT05147220
Understanding Multiple Sclerosis and the REMODEL-1 Study
Comprender la esclerosis múltiple y el estudio REMODEL-1
Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson’s Disease.
ClinicalTrials.gov Identifier: NCT05424276